Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / COM
-
Number of holders
-
142
-
Total 13F shares, excl. options
-
24,633,284
-
Shares change
-
-2,077,473
-
Total reported value, excl. options
-
$568,533,323
-
Value change
-
-$49,482,314
-
Put/Call ratio
-
144%
-
Number of buys
-
54
-
Number of sells
-
-87
-
Price
-
$23.08
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q1 2021
210 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q1 2021.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 142 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24,633,284 shares
.
Largest 10 shareholders include VANGUARD GROUP INC (3,296,117 shares), FMR LLC (2,869,051 shares), STATE STREET CORP (2,835,342 shares), FIRST TRUST ADVISORS LP (2,566,018 shares), BlackRock Inc. (2,466,443 shares), JPMORGAN CHASE & CO (965,351 shares), CITADEL ADVISORS LLC (730,128 shares), MACQUARIE GROUP LTD (665,762 shares), Samsara BioCapital, LLC (640,688 shares), and JACOBS LEVY EQUITY MANAGEMENT, INC (532,102 shares).
This table shows the top 142 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.